Massachusetts’ biopharma industry — one of the world’s biggest life-sciences hubs — is telling two very different stories at once: booming investment alongside falling employment.
According to the Massachusetts Biotechnology Council (MassBio) annual snapshot released in August 2026, the money is flowing. Venture funding hit $3.45 billion in the first half of 2026, up 25% year over year, and eight Massachusetts biopharmas went public in the first half (versus just two in all of 2025). Dealmaking was strong too, including Biogen’s $5.6 billion acquisition of Apellis and multiple Eli Lilly buyouts of local firms. The state still leads the nation with 63.2 million square feet of lab space.
The other side
Yet employment fell 3% (about 3,605 jobs), from 117,108 to 113,503, as large employers like Takeda, Moderna and Bristol Myers Squibb cut headcount through restructuring and pipeline reprioritization. Early-stage “seed” funding plunged 39%, NIH grant awards slipped 6%, and the lab vacancy rate climbed to 31% (from 28%). One industry figure summed up the worry about fewer federal grant opportunities as “fewer shots on goal.”
Why it matters
The split — thriving growth-stage companies and investors on one side, contracting incumbents and softer early-stage and public funding on the other — is a useful barometer for the broader biotech sector. Capital is returning after a long slump, but the recovery is uneven, and job growth hasn’t followed the money.